/Medtronic%20Plc%20logo%20on%20phone-by%20rafapress%20via%20Shutterstock.jpg)
Valued at a market cap of $107.6 billion, Medtronic plc (MDT) develops, manufactures, and sells medical devices and therapies to healthcare systems, physicians, clinicians, and patients. The Galway, Ireland-based company is scheduled to announce its fiscal Q4 earnings for 2026 in the near future.
Before this event, analysts expect this healthcare company to report a profit of $1.58 per share, down 2.5% from $1.62 per share in the year-ago quarter. The company has topped Wall Street’s bottom-line estimates in each of the last four quarters. Its earnings of $1.36 per share in the previous quarter outpaced the consensus expectations by 2.3%.
For the current fiscal year, ending in April, analysts expect MDT to report a profit of $5.57 per share, representing a 1.5% increase from $5.49 per share in fiscal 2025. Furthermore, its EPS is expected to grow 9.3% year-over-year to $6.09 in fiscal 2027.
MDT has declined 1.3% over the past 52 weeks, considerably underperforming both the S&P 500 Index's ($SPX) 32.2% return and the State Street Health Care Select Sector SPDR ETF’s (XLV) 5% uptick over the same time period.
On Feb. 17, Medtronic reported stronger-than-expected Q3 results. Its revenue rose 8.7% year over year to $9.02 billion, with organic revenue up 6%. However, its adjusted EPS declined to $1.36 from $1.39 reported in the prior-year quarter, which might have lowered investor confidence over its profitability, leading to a 3.1% drop in its shares that day.
Wall Street analysts are moderately optimistic about MDT’s stock, with a "Moderate Buy" rating overall. Among 28 analysts covering the stock, 13 recommend "Strong Buy," two indicate "Moderate Buy,” and 13 suggest "Hold." The mean price target for MDT is $107.43, indicating a 29% potential upside from the current levels.
